FIELD: organic compounds.
SUBSTANCE: invention relates to organic compounds useful for the treatment or prevention of diseases in mammals. The invention provides new compounds that have the general formula (I) or (II), where R2, R3, R5, R99, W, Y and Z are presented in the claims, and a pharmaceutical composition containing these compounds.
EFFECT: compounds have the activity of a positive allosteric modulator of GABAA receptors α5 and can be used to treat or prevent Alzheimer's disease, mild cognitive impairment, age-related cognitive decline, negative and/or cognitive symptoms associated with schizophrenia, bipolar disorder, autism spectrum disorder, Angelman syndrome, Rett syndrome, Prader-Willi syndrome, epilepsy, post-traumatic stress disorder, amyotrophic lateral sclerosis, fragile X disorder.
14 cl, 2 tbl, 335 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ETERIAL DERIVATIVES OF ISOXAZOLE AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A ALFA 5 RECEPTOR | 2017 |
|
RU2772862C2 |
| AMINOQUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | 2020 |
|
RU2821714C2 |
| PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
| DERIVATIVES OF BENZIMIDAZOL INHIBITING FACTOR Xa | 2004 |
|
RU2346944C2 |
| INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | 2014 |
|
RU2666532C2 |
| N-PIPERIDIN-3-YL-BENZAMIDE DERIVATIVES FOR CARDIOVASCULAR DISEASES TREATMENT | 2014 |
|
RU2618628C1 |
| NOVEL CYCLOPENTANE DERIVATIVES | 2010 |
|
RU2572555C2 |
| DERIVATIVES OF N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDES AND THEREOF APPLICATION AS PDE10A INHIBITORS | 2011 |
|
RU2562066C2 |
| DERIVATIVES OF 3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID AS KMO INHIBITORS | 2014 |
|
RU2693016C1 |
| NOVEL COMPOUNDS 3,4-DIHYDRO-2N-ISOQUINOLIN-1-ONE AND 2,3-DIHYDROISOINDOL-1-ONE | 2014 |
|
RU2693698C2 |
